Crizotinib as Salvage and Maintenance With Allogeneic Stem Cell Transplantation for Refractory Anaplastic Large Cell Lymphoma
The NPM-ALK fusion protein is found in ALK+ anaplastic large cell lymphomas harboring the t(2;5) chromosomal translocation. Patients harboring ALK translocations typically have an excellent prognosis with conventional chemotherapy and a reported 5-year survival rate of 70%. Although most patients with ALK+ anaplastic large cell lymphoma have a good prognosis, some patients do not respond to standard therapies. In patients with refractory anaplastic large cell lymphoma who can achieve remission, allogeneic stem cell transplant is a potentially curative option. This article describes a patient with refractory ALK+ anaplastic large cell lymphoma who experienced a complete response to the ALK inhibitor crizotinib and then underwent an allogeneic stem cell transplant followed by crizotinib maintenance therapy.
Target Audience
This activity has been designated to meet the educational needs of physicians and nurses involved in the management of patients with cancer.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Discuss the clinical activity of crizotinib in the management of patients with anaplastic large cell lymphoma
James M. Cleary, MD, PhD
Dana-Farber Cancer Institute, Harvard Medical School
Boston, Massachusetts
Scott Rodig
Brigham and Women’s Hospital, Harvard Medical School
Boston, Massachusetts
Paul M. Barr
University of Rochester Medical Center, University of Rochester
Rochester, New York
Atul B. Shinagare
Dana-Farber Cancer Institute, Harvard Medical School
Boston, Massachusetts
Jeffrey W. Clark
Massachusetts General Hospital, Harvard Medical School
Boston, Massachusetts
Geoffrey I. Shapiro
Dana-Farber Cancer Institute, Harvard Medical School
Boston, Massachusetts
Philippe Armand
Dana-Farber Cancer Institute, Harvard Medical School
Boston, Massachusetts
Available Credit
- 1.00 Participation
- 1.00 Nurse
- 1.00 Physician
Price
Required Hardware/software
To access this activity, users will need:
- A device with an Internet connection
- Adobe Reader or other PDF reader software for article and certificate viewing/printing